what we fund.
International evidence shows patients have better outcomes on a clinical trial but unfortunately, due to our small population, Australian patients are rarely included in blood cancer (leukaemia, myeloma & lymphoma) trials. It is therefore imperative that clinical trials are initiated here in Australia.
Snowdome is the only not for profit organisation that is exclusively focussed on raising funds to support translational research into blood cancers, accelerating access to next-generation treatments for Australian patients to help them live longer, better lives.
Over 85% of Snowdome’s available funds have been invested in cutting-edge research. Snowdome’s focus is to identify the right blood cancer patient for the right drugs.
Snowdome has a strategic granting process that identifies key pillars to fight blood cancer including:
> epigenetics – the chemical reactions that switch on/off genes;
> genomics/ precision (personalised) medicine – matching the cancer’s mutations to a drug treatment;
> immune therapies – boosting the immune system to fight cancers;
> monoclonal antibodies – golden bullets that bind onto and kill the cancer cell;
> pro-apoptotic agents – to make an immortal cell commit suicide and
> targeting the microenvironment – making the cancer cell’s environment hostile to its growth.
the wilson centre for lymphoma genomics
An incredibly generous donation from Christine and Bruce Wilson of $5.5 million to Snowdome in 2017 led to the development of the state-of-the-art centre for genomic testing at the Peter MacCallum Cancer Centre. Genomic testing involves analysing a patient’s blood sample to look for critical gene mutations that are known to play a role in their particular blood cancer. The results of the test provide a more accurate diagnosis, prognosis and treatment journey. 60% of tests provide a clinically relevant finding. That is a corrected diagnosis, an altered prognosis or a different course of treatment. For some the results are literally life saving.
blood cancer research western australia
With the generosity of Snowdome, Blood Cancer Research WA was established in April 2018 under the leadership of Associate Professor Chan Cheah. The centre aims to bring blood cancer trials to the west enabling Western Australian patients to access potentially life-saving treatments right at home. The number of patients accessing trials has increased dramatically and the wait time to access a trial has decreased since the inception of Blood Cancer Research WA.
australasian lymphoma alliance
Snowdome is proud to be a supporter of The Australasian Lymphoma Alliance (ALA), a working party of clinicians focused on retrospective clinical data analysis & tissue research, guideline development, facilitation of case-based discussions and information sharing within the lymphoma community. It offers the community a peak body of experts with a dedicated interest in lymphoma who work with organisations to promote, facilitate and engage in improving outcomes for lymphoma patients.
women in lymphoma
Snowdome is proud to be a supporter of Women in Lymphoma (WiL). Formed in mid-2019, WiL is an international network of female professional peers engaged in the treatment and research of lymphoma. This global alliance of lymphoma clinicians and researchers provides support and advocacy for greater leadership of women in lymphoma research. Believing that “where there’s a WiL there’s a way”, WiL is committed to advancing collaborative and meaningful contributions to lymphoma research, teaching and patient care globally from its membership base.
Research we fund.
Since 2010, Snowdome Foundation has extended 52 grants enabling more than 71 funded research positions. Over 85% of Snowdome’s available funds have been committed to cutting-edge research. Snowdome’s focus on multi-year funding has ensured research trials, biomarkers and projects have run to completion and are supporting Australian blood cancer patients.
call for grants.
The Snowdome Foundation’s $5,000 award for outstanding blood cancer research aims to recognise and celebrate the achievements of one of Australia’s best and brightest mid-career blood cancer researchers who has made a significant advance in blood cancer research.
The $5,000 HSANZ/Snowdome Foundation Mid-Career Grant will cover educational support such as tuition, registration fees and travel for courses and meetings that are integral to an award winner’s career development plan, as well as research project expenses that can aid in his/her professional development. If the research is presented at a conference, Snowdome requests recognition within the presentation.
|Promotion and call for nominations||18 March – 30 July 2021|
|Nomination closing date||Friday 30 July 2021|
|HSANZ Review Panel nomination ranking and award recommendation||August 2021|
|Communication with applicants||Early September 2021|
|Announcement of Award||Blood Conference Gala Dinner 21 September 2021, Adelaide
HSANZ e-news, Snowdome e-news and website
To be eligible for this award applicants must be:
- Mid-career cancer researcher – defined as someone who has more than 5 years, but less than postdoctoral experience in blood cancer research. (Defined as date of PhD award or equivalent degree. Effective July 30 2021, with consideration provided for appropriate career disruption).
- The applicant must be an active cancer researcher employed by an Australian University, Research Institute or Health Service
- Have an outstanding track record of publication in blood cancer research, including publications within the last 24 months.
- Be responsible for the major components of the research (first or senior researcher)
- Be a Member of HSANZ
Nominations must include the following documentation and be emailed in a single PDF file to [email protected] by no later than 5pm EST Friday 30 July 2021:
- A completed nomination form (self-nominations accepted)
- A copy of the nominee’s current Curriculum Vitae (max 3 pages)
- A copy of the relevant publication
- A supporting statement from the nominator detailing why the nominee is deserving of the award (refer to selection criteria 2). This would usually be the applicant’s supervisor , department, clinical or Institute Director. This must be on letterhead and signed.
- A supporting statement from an independent senior research leader in the field outlining why the nominee is deserving of the award (refer to selection criteria 2). This must be on company letterhead, signed and emailed directly to HSANZ. The pdf should be named SNOWDOME HSANZ AWARD [FamilyName First name] and submitted by email, to HSANZ at: [email protected]
This $5000 award will go to the mid-career blood cancer researcher who has made the most significant advance in blood cancer research over the preceding 18-24 months. Applicants will be competitively ranked by a panel of multidisciplinary Australian blood cancer research leaders, according to the following criteria:
CRITERIA 1. Scientific quality of research (50%) – demonstrated by a significant peer-reviewed blood cancer research publication/s that advances our understanding of blood cancer prevention, early detection, diagnosis, management or treatment, or improvement of quality of life for blood cancer patients.
CRITERIA 2. Research impact and innovation (25%) – demonstrated by supporting letters from professional nominators. For example, this may highlight the nominee’s:
- Contribution of the research program to blood cancer research in Australia and internationally
- Potential of published research to innovate patient care and/or health service improvement
- Evidence of collaboration
CRITERIA 3. Leadership and contribution to haematology (25%). This criterion will focus on the individual’s contribution to blood cancer research in Australia, including academic and clinical leadership roles, supervision, advocacy and/or policy. This includes contribution to HSANZ.
The award winner will be advised of the prize in early-September 2021 prior to the Blood conference which will be held in Adelaide from 19-22 September 2021. The candidate will be invited to attend the Gala Dinner on Tuesday 21 September 2021 to officially accept their award.
Friday 30 July at 5:00 pm
Electronic applications, along with all supporting documents should be submitted as a single pdf.
The pdf should be named SNOWDOME HSANZ AWARD [FamilyName First name] and submitted by email, to HSANZ at: [email protected]
Research projects need to be aligned with Snowdome’s mission, vision and values. The project should be cutting-edge and aim to improve the outcomes of Australians living with blood cancers to help them lead healthy, longer lives.
Researchers are encouraged to register to find out about upcoming research grant opportunities.
The research project should:
deliver new therapies to blood cancer patients in the foreseeable future
involve Australian researchers in Australia or living overseas and involve new therapies that are part of the ‘new pillars’ for therapy
have quantifiable outcomes and reasonable milestones, set and agreed upon in advance
encourage research (clinical or laboratory) that identifies patients that are likely to benefit from new therapies (that exist now/foreseeable future)
The research project shouldn’t:
be research equipment
be basic research that does not eventuate into clinical treatments in the foreseeable future
predominantly involve supportive care, psycho-social support, housing, transport